Extreme Hyperhemolysis Syndrome in a Patient With Sickle Cell Disease Successfully Managed With Eculizumab: A Case of Survival at 1.2 g/dL Hemoglobin

Read full text Summarise with VIRAT
Authors: Isa Cordeiro, Carolina Cerca, Marta Isabel Pinheiro, Claudia Pratas, Nuno Germano
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This case presents a 26-year-old male with sickle cell disease (SCD) who experienced a catastrophic hyperhemolysis syndrome (HHS) triggered by red blood cell (RBC) transfusion. The patient was initially hospitalized for a vaso-occlusive crisis and fever; the patient's clinical status deteriorated rapidly as his hemoglobin (Hb) plummeted from 7.5 g/dL to a nadir of 1.2 g/dL. Despite treatment with corticosteroid and intravenous immunoglobulin (IVIG) therapy, the hemolytic process persisted. To manage the critical imbalance between oxygen delivery and demand, invasive mechanical ventilation was initiated as a supportive metabolic measure. Due to the failure of conventional therapies, eculizumab was administered on the third day of intensive care unit (ICU) admission. This intervention resulted in the cessation of hyperhemolysis, followed by gradual hematological stabilization and recovery. This report underscores the severity of HHS and demonstrates the successful use of terminal complement inhibition as a life-saving rescue strategy in extreme cases.

Fields of Study & Subjects

Hemoglobinopathies and Related Disorders Complement system in diseases Blood transfusion and management

Publication details

Journal / source
Cureus
Volume
18
Issue
3
Pages
e106034–e106034
Publication date
28 March 2026
Language
EN